The Cancer Team at Bellin Health offers clinical trials for the treatment and prevention of many forms of cancer. Check back regularly for frequent updates or for more information, please call us at 920 435-8326.
Brain - No studies open to accrual studies at this time.
High Risk Hormone Receptor –Positive /HER2 Negative
ID Number: S1207 Principal Investigator: Dr. Hassan Tahsildar
Title: A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy
Purpose: The purpose of this study is to compare whether the addition of one year of everolimus to standard adjuvant endocrine therapy improves invasive disease-free survival in patients with high-risk, hormone-receptor (HR) positive and HER2-negative breast cancer.
ID Number: S1501 Principal Investigator: Dr. Hassan Tahsildar
Title: Prospective Evaluation Of Carvedilol In Prevention Of Cardiac Toxicity In Patients with Metastatic Her-2+ Breast Cancer
Purpose: The purpose to assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab–based HER-2 targeted therapy.
ID Number: A011401 Principal Investigator: Dr. Hassan Tahsildar
Title: A Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer: The BWEL Study
Purpose: The purpose of this study is to see if losing weight may help prevent breast cancer from coming back.
ID Number: A011502 Principal Investigator: Dr. Hassan Tahsildar
Title: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy For Node Positive HER2 Negative Breast Cancer: The ABC Trial
Purpose: The purpose of this study is to compare any good and bad effects of using aspirin after someone has completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer.
Node Positive Breast Cancer
ID Number: A011202 Principal Investigator: Dr. Charlie Pan
Title: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection To Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Purpose: To evaluate whether radiation to the undissected axilla and regional lymph nodes is not inferior to axillary lymph node dissection with radiation to the regional lymph nodes but not to the dissected axilla in terms of invasive breast cancer recurrence-free interval in patients with positive SLN(s) after completion of neoadjuvant chemotherapy
Gastrointestinal/Pancreas - No studies open to accrual studies at this time.
Gynecology - No studies open to accrual studies at this time.
Newly Diagnosed Symptomatic Multiple Myeloma
ID Number: E1A11 Principal Investigator: Dr. Hassan Tahsildar
Title: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Phase: Phase III
Purpose: Primary Objectives are to compare the complete remission (CR) rate of BR versus BVR as induction therapy and to compare the 1-year post-induction disease-free survival (DFS) rate with rituximab plus lenalidomide to rituximab alone as continuation therapy.
Extensive Stage Small Cell Lung Cancer
ID Number: EA5161 Principal Investigator: Dr. Hassan Tahsildar
Title: A Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Purpose: The purpose of this research study is to compare any good and bad effects of using nivolumab (OPDIVO®) along with the usual chemotherapy regimen of cisplatin/carboplatin and etoposide to using the usual chemotherapy approach alone.
Unresectable Stage III/IV
ID Number: EA6141 Principal Investigator: Dr. Hassan Tahsildar
Title: A Randomized Phase II/III Study Of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Phase: Phase II/III
Purpose: The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab together. It is also to evaluate what effects, good and bad, that this combination of drugs may have on your cancer.
(Temporarily closed to accrual effective 6/23/17)
Advanced BRAFV600 Mutant Melanoma
ID Number: EA6134 Principal Investigator: Dr. Hassan Tahsildar
Title: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Phase: Phase III
Purpose: The purpose of this research study is to compare the good and bad effects of the sequence of immunotherapy followed by BRAF inhibitor therapy if and when the disease becomes resistant, to the sequence of BRAF inhibitor therapy followed by immunotherapy if and when the disease becomes resistant.